Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel
NASDAQ:BMEA

Biomea Fusion Q1 2025 Earnings Report

Biomea Fusion logo
$1.16 -0.04 (-3.33%)
Closing price 06/16/2026 04:00 PM Eastern
Extended Trading
$1.22 +0.06 (+5.17%)
As of 05:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Biomea Fusion EPS Results

Actual EPS
-$0.80
Consensus EPS
-$0.84
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Biomea Fusion Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biomea Fusion Announcement Details

Quarter
Q1 2025
Date
5/5/2025
Time
Before Market Opens
Conference Call Date
Monday, May 5, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Biomea Fusion's Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled on Friday, July 31, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Biomea Fusion's Q1 2025 Press ReleasePress Release
(8-K)
Biomea Fusion's Q1 2025 Quarterly reportQuarterly report
(10-Q)

Biomea Fusion Earnings Headlines

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of ...
June 5, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/biomea-fusion-presents-new-clinical-and-translational-data-for-icovamenib-at-the-american-diabetes-association-ada-86th-scientific-sessions-and-announces-expansion-of-ongoing-phase-i-bmf-650-study-1036229769
Biomea Fusion Presents Promising Clinical Data for Icovamenib and Expands Phase I Study of BMF-650 at ADA 2026
June 5, 2026  |  quiverquant.comQ
SpaceX will crumble without these 5 companies
The SpaceX IPO is drawing near, but the real opportunity may lie in 5 lesser-known companies providing the critical infrastructure SpaceX depends on to operate. Goldman Sachs and Morgan Stanley are reportedly already building positions in one of these names. Another is a resource miner that Elon Musk's broader empire - including Tesla - relies on. Lance Ippolito has detailed all five inside his free SpaceX Investing Blackbook.tc pixel
June 17 at 1:00 AM  |  InvestPub (Ad)
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
June 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/05/3307662/0/en/biomea-fusion-presents-new-clinical-and-translational-data-for-icovamenib-at-the-american-diabetes-association-ada-86th-scientific-sessions-and-announces-expansion-of-ongoing-phase.html
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
June 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/03/3305979/0/en/biomea-fusion-announces-research-collaboration-with-university-of-leicester-to-evaluate-icovamenib-in-combination-with-semaglutide-in-obesity.html
Biomea Fusion to Participate at Upcoming Investor Conferences
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3293383/0/en/biomea-fusion-to-participate-at-upcoming-investor-conferences.html
See More Biomea Fusion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biomea Fusion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomea Fusion and other key companies, straight to your email.

About Biomea Fusion

Biomea Fusion (NASDAQ:BMEA) (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction. BMF-219 is currently undergoing early-phase clinical evaluation in patients with MLL-rearranged leukemias and other malignancies driven by dysregulated menin activity. In parallel, Biomea Fusion is advancing a pipeline of preclinical programs targeting additional epigenetic and chromatin-associated proteins, all developed using its integrated discovery platform.

Founded in 2018, Biomea Fusion has assembled a multidisciplinary team of drug discovery scientists, clinical development experts and regulatory specialists. The company conducts its research and early clinical operations in the United States and is actively exploring collaborations to support later‐stage development and global commercialization. With its focus on epigenetic modulation in oncology, Biomea Fusion seeks to deliver novel treatment options for patients facing unmet medical needs.

View Biomea Fusion Profile
Earnings Tools